Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory Lymphomas”

2,146 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 2,146 results

Testing effectiveness (Phase 2)UnknownNCT03245905
What this trial is testing

Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHL

Who this might be right for
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)
Sun Yat-sen University 100
Testing effectiveness (Phase 2)Study completedNCT00576979
What this trial is testing

Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

Who this might be right for
Leukemia
City of Hope Medical Center 51
Testing effectiveness (Phase 2)Study completedNCT00967369
What this trial is testing

Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment.

Who this might be right for
Recurrent Classic Hodgkin LymphomaRefractory Classic Hodgkin Lymphoma
M.D. Anderson Cancer Center 20
Early research (Phase 1)Study completedNCT01212341
What this trial is testing

Allogeneic Natural Killer (NK) Cell Therapy in Patients With Lymphoma or Solid Tumor

Who this might be right for
Malignant LymphomasSolid Tumors
Seoul National University Hospital 18
Testing effectiveness (Phase 2)UnknownNCT02060656
What this trial is testing

Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)

Who this might be right for
Diffuse Large B-Cell Lymphoma
Royal Marsden NHS Foundation Trust 92
Testing effectiveness (Phase 2)Ended earlyNCT06912529
What this trial is testing

Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma

Who this might be right for
B-cell Lymphoma RefractoryB-cell Lymphoma Recurrent
Universität Münster 1
Large-scale testing (Phase 3)Active Not RecruitingNCT05409066
What this trial is testing

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

Who this might be right for
Follicular Lymphoma (FL)
Genmab 549
Early research (Phase 1)Study completedNCT02568553
What this trial is testing

Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

Who this might be right for
Recurrent Burkitt LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Grade 1 Follicular Lymphoma+23 more
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)Ended earlyNCT02420795
What this trial is testing

Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Central Nervous System LymphomaGastric Mantle Cell LymphomaRecurrent Mantle Cell Lymphoma+4 more
M.D. Anderson Cancer Center 16
Testing effectiveness (Phase 2)Study completedNCT03192202
What this trial is testing

AFM13 in Relapsed/Refractory Cutaneous Lymphomas

Who this might be right for
Lymphoma, T-Cell, Cutaneous
Ahmed Sawas 18
Early research (Phase 1)Active Not RecruitingNCT05784441
What this trial is testing

JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)

Who this might be right for
Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Janssen Research & Development, LLC 21
Testing effectiveness (Phase 2)UnknownNCT05137886
What this trial is testing

PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma

Who this might be right for
Hodgkin Lymphoma, AdultRelapseRefractory Hodgkin Lymphoma
Institute of Hematology & Blood Diseases Hospital, China 47
Testing effectiveness (Phase 2)Study completedNCT05844956
What this trial is testing

DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1)

Who this might be right for
Lymphoma, Non-Hodgkin
Dizal Pharmaceuticals 17
Testing effectiveness (Phase 2)Study completedNCT02600897
What this trial is testing

Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Who this might be right for
Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche 114
Testing effectiveness (Phase 2)Study completedNCT00156013
What this trial is testing

Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)

Who this might be right for
Lymphoma, B-CellLymphoma, Non-Hodgkin
Oncology Specialists, S.C. 33
Early research (Phase 1)Study completedNCT01567709
What this trial is testing

Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma

Who this might be right for
Adult B Acute Lymphoblastic LeukemiaAdult T Acute Lymphoblastic LeukemiaAnaplastic Large Cell Lymphoma+32 more
National Cancer Institute (NCI) 34
Testing effectiveness (Phase 2)Study completedNCT02824029
What this trial is testing

Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Who this might be right for
Classical Hodgkin LymphomaRecurrent Hodgkin LymphomaRefractory Hodgkin Lymphoma
Barbara Ann Karmanos Cancer Institute 28
Testing effectiveness (Phase 2)WithdrawnNCT04882163
What this trial is testing

Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma

Who this might be right for
Lymphoma, B-Cell
Celgene
Testing effectiveness (Phase 2)Study completedNCT00003887
What this trial is testing

Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation

Who this might be right for
Breast CancerChronic Myeloproliferative DisordersGestational Trophoblastic Tumor+9 more
Fred Hutchinson Cancer Center
Large-scale testing (Phase 3)UnknownNCT04342936
What this trial is testing

Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

Who this might be right for
Classical Hodgkin Lymphoma
Jiangsu HengRui Medicine Co., Ltd. 56
Next Page